BeyondSpring Inc.
| NASDAQ: BYSI | Healthcare / Biotechnology / USA |
| 0.7900 | -0.0400 | -4.82% | Vol 17.73K | 1Y Perf -30.83% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 0.7600 | ASK | 0.8240 | ||
| Open | 0.7701 | Previous Close | 0.8300 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 1.00 | Analyst Rating | Moderate Buy 2.50 | |
| Potential % | 26.58 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 46.62 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 8.53 | Earnings Rating | Neutral | |
| Market Cap | 30.75M | Earnings Date | 18th Jul 2023 | |
| Alpha | 0.01 | Standard Deviation | 0.47 | |
| Beta | 0.17 |
Today's Price Range 0.73750.8250 | 52W Range 0.54203.45 | 5 Year PE Ratio Range -22.60-7.40 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -14.04% | ||
| 1 Month | -14.12% | ||
| 3 Months | -34.71% | ||
| 6 Months | -30.70% | ||
| 1 Year | -30.83% | ||
| 3 Years | -93.98% | ||
| 5 Years | -96.84% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -103.74 | |||
ROE last 12 Months | -111.59 | |||
ROA (5Y Avg) | -32.86 | |||
ROA last 12 Months | -64.60 | |||
ROC (5Y Avg) | -241.95 | |||
ROC last 12 Months | -104.44 | |||
Return on invested Capital Q | -26.35 | |||
Return on invested Capital Y | -26.35 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 2.54 | ||||
| 171.41 | ||||
| - | ||||
| -3.50 | ||||
| -1.21 | ||||
| 2.54 | ||||
| 0.69 | ||||
| -1 056 680.00 | ||||
| Forward PE | -0.82 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.80 | ||||
| 5.00 | ||||
| 0.05 | ||||
| 0.13 | ||||
| -742.00 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -4 778.00 | ||||
| -4 773.50 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 338.00K | ||||
| 0.01 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2021 | - | -0.24 | - |
| Q03 2021 | -0.58 | -0.47 | 18.97 |
| Q02 2021 | -0.49 | -0.49 | 0.00 |
| Q01 2021 | -0.54 | -0.44 | 18.52 |
| Q04 2020 | - | -0.52 | - |
| Q03 2020 | -0.54 | -0.48 | 11.11 |
| Q02 2020 | -0.57 | -0.46 | 19.30 |
| Q01 2020 | -0.45 | -0.58 | -28.89 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2022 QR | -0.23 | 0.00 | - |
| 12/2022 QR | -0.28 | 0.00 | - |
| 12/2023 FY | -2.49 | 0.00 | - |
| 12/2024 FY | -1.12 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 17.73K |
| Shares Outstanding | 38.92K |
| Shares Float | 23.61M |
| Trades Count | 80 |
| Dollar Volume | 13.95K |
| Avg. Volume | 40.08K |
| Avg. Weekly Volume | 37.92K |
| Avg. Monthly Volume | 41.73K |
| Avg. Quarterly Volume | 40.59K |
BeyondSpring Inc. (NASDAQ: BYSI) stock closed at 0.79 per share at the end of the most recent trading day (a -4.82% change compared to the prior day closing price) with a volume of 17.73K shares and market capitalization of 30.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 61 people. BeyondSpring Inc. CEO is Lan Huang.
The one-year performance of BeyondSpring Inc. stock is -30.83%, while year-to-date (YTD) performance is -57.98%. BYSI stock has a five-year performance of -96.84%. Its 52-week range is between 0.542 and 3.45, which gives BYSI stock a 52-week price range ratio of 8.53%
BeyondSpring Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 2.54, a price-to-sale (PS) ratio of 171.41, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -64.60%, a ROC of -104.44% and a ROE of -111.59%. The company’s profit margin is -%, its EBITDA margin is -4 773.50%, and its revenue ttm is $338.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from BeyondSpring Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BeyondSpring Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BeyondSpring Inc. is Moderate Buy (2.5), with a target price of $1, which is +26.58% compared to the current price. The earnings rating for BeyondSpring Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BeyondSpring Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BeyondSpring Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.46, ATR14 : 0.07, CCI20 : -213.25, Chaikin Money Flow : 0.41, MACD : -0.04, Money Flow Index : 27.84, ROC : -13.13, RSI : 34.91, STOCH (14,3) : 27.83, STOCH RSI : 0.00, UO : 55.34, Williams %R : -72.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BeyondSpring Inc. in the last 12-months were:
BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China.
CEO: Lan Huang
Telephone: +1 646 305-6387
Address: 28 Liberty Street, New York 10005, NY, US
Number of employees: 61
